Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in neutrophils | 0.75 |
| chemistry Open Targets | compounds already reach it: rovelizumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 659 | 0.71 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress ITGAM in microglia; measure IL-1β and TNF release and surface HLA-DR and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of ITGAM in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- ITGAM in dopamine neurons, braak-0.55 (p 0.125) → +0.18 (p 0.638)receipt 4501
- ITGAM in microglia, braak+0.04 (p 0.910) → -0.18 (p 0.646)receipt 4500
Swarm cases
receipt 4501: ITGAM in dopamine neurons, braak
- power
- full sample -0.06 (p 0.820, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.728, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.555, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.08, sign flips 2; without severely affected donors -0.06 (p 0.820, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGAM in dopamine neurons.
case closed: nothing better to follow up.
receipt 4500: ITGAM in microglia, braak
- power
- full sample -0.06 (p 0.814, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.728, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.04 (p 0.888, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.06, sign flips 3; without severely affected donors -0.06 (p 0.814, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGAM in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts